跳转至内容
Merck
CN

234599

Sigma-Aldrich

环己烯四醇 B 环氧化物

≥98% (HPLC), solid, Glucocerebrosidase inhibitor, Calbiochem®

别名:

环己烯四醇 B 环氧化物

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C6H10O5
CAS Number:
6090-95-5
分子量:
162.14
MDL编号:
MFCD27918490
UNSPSC代码:
12352119
NACRES:
NA.77

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

环己烯四醇 B 环氧化物, Conduritol B Epoxide, CAS 6090-95-5, is an irreversible Inhibitor of glucocerebrosidase in neurons. Also inhibits α-glucosidase activity in a variety of species.

质量水平

100

方案

≥98% (HPLC)

表单

solid

制造商/商品名称

Calbiochem®

储存条件

OK to freeze
desiccated

颜色

white

溶解性

DMSO: soluble
water: soluble

运输

ambient

储存温度

−20°C

SMILES字符串

O1[C@@H]2[C@H]1[C@@H]([C@H]([C@@H]([C@H]2O)O)O)O

InChI

1S/C6H10O5/c7-1-2(8)4(10)6-5(11-6)3(1)9/h1-10H/t1-,2-,3+,4+,5-,6+/m0/s1

InChI key

ZHMWOVGZCINIHW-FTYOSCRSSA-N

相关类别

一般描述

抑制哺乳动物、蜗牛、甜杏仁和酵母中的 α-葡萄糖苷酶活性。是培养神经元过程中葡萄糖脑苷脂酶的不可逆、强效和特异性抑制剂。还有研究表明，还可抑制来自酵母和兔肠道蔗糖酶-异麦芽糖酶复合物的 α-葡萄糖苷酶。

生化/生理作用

主要靶标
α-葡萄糖苷酶
产物不与ATP竞争。
可逆：否
细胞渗透性：否

制备说明

溶液中不稳定；仅在使用前进行复溶。

其他说明

2024年CiteAb奖——成功的帕金森研究供应商(2024 CiteAb Award Winner for Supplier Succeeding in Parkinson′s Research)

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

毒性：有害（C）

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Oeystein Roed Brekk et al.
Proceedings of the National Academy of Sciences of the United States of America, 117(44), 27646-27654 (2020-10-17)
Neurons are dependent on proper trafficking of lipids to neighboring glia for lipid exchange and disposal of potentially lipotoxic metabolites, producing distinct lipid distribution profiles among various cell types of the central nervous system. Little is known of the cellular
Azucena Perez-Canamas et al.
Brain communications, 3(1), fcaa200-fcaa200 (2021-04-03)
TMEM106B is a transmembrane protein localized to the endo-lysosomal compartment. Genome-wide association studies have identified TMEM106B as a risk modifier of Alzheimer's disease and frontotemporal lobar degeneration, especially with progranulin haploinsufficiency. We recently demonstrated that TMEM106B loss rescues progranulin null
Electra Brunialti et al.
Journal of neuroinflammation, 18(1), 220-220 (2021-09-24)
Homozygotic mutations in the GBA gene cause Gaucher's disease; moreover, both patients and heterozygotic carriers have been associated with 20- to 30-fold increased risk of developing Parkinson's disease. In homozygosis, these mutations impair the activity of β-glucocerebrosidase, the enzyme encoded
Kelly E Glajch et al.
Proceedings of the National Academy of Sciences of the United States of America, 118(31) (2021-07-31)
Loss-of-function mutations in acid beta-glucosidase 1 (GBA1) are among the strongest genetic risk factors for Lewy body disorders such as Parkinson's disease (PD) and Lewy body dementia (DLB). Altered lipid metabolism in PD patient-derived neurons, carrying either GBA1 or PD
Iva Stojkovska et al.
Neuron, 110(3), 436-451 (2021-11-19)
Neurodegenerative disorders are characterized by a collapse in proteostasis, as shown by the accumulation of insoluble protein aggregates in the brain. Proteostasis involves a balance of protein synthesis, folding, trafficking, and degradation, but how aggregates perturb these pathways is unknown.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持